Trinity Biotech's American depositary receipts surged after the company received approval from New York regulators to start providing tests that assess the risk of preeclampsia in pregnant patients.

Trinity Biotech reported a 3% increase in Q3 2024 revenue to $15.2 million, driven by strong demand for its TrinScreen HIV business. The company also highlighted significant growth in its Point-of ...

Trinity Biotech plc, a biotechnology company specializing in diagnostics and diabetes management, has announced the upcoming release of its flagship product, CGM+, a next-generation wearable ...

BOSTON (CBS.MW) -- Biotechnology stocks moved higher on Monday, with shares of Trinity Biotech soaring after the Irish company said it won U.S. clearance for its 10-minute HIV test. U.S.-listed ...